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ABSTRACT  42 
Objective 43 
Optimisation of nonprescription medicine (NPM) supply from community pharmacies could 44 
reduce demand on other healthcare providers, including general practitioners and emergency 45 
department personnel.  Outcomes can be maximised if patients disclose relevant information 46 
e.g. concomitant medication, during pharmacy-based consultations.  Strategies to promote 47 
information disclosure are needed.  This study used the Psychometric Paradigm of Risk to 48 
explore whether the public’s risk perception of NPMs was associated with information 49 
disclosure. 50 
Methods 51 
This national, cross-sectional population study used a random sample of 3000 adults (aged >18 52 
years) from the Scottish Electoral register. Postal questionnaires collected data on risk 53 
perceptions, information disclosure and demographic information. Exploratory factor analysis 54 
was used to determine constructs to which the risk questions could be grouped. Factors were 55 
scored and the scores compared across demographics. 56 
Key Findings 57 
Just over half (57%) of the 927 respondents perceived NPMs to be associated with low general 58 
risk. For 19 of the 23 statements (83%), respondents indicated general agreement i.e. low risk 59 
perception of OTC medicines. Individuals with higher risk perception of NPMs were less likely 60 
to disclose information during consultations compared with respondents with lower risk 61 
perception.   62 
Conclusion  63 
There is general low public risk perception of NPMs. Individuals with higher risk perception 64 
are less likely to disclose information. Interventions that raise risk perception are unlikely to 65 
enhance the safe and effective supply of NPMs. 66 
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INTRODUCTION  67 
 68 
Nonprescription medicines (NPMs) enable patients to manage conditions without recourse to 69 
health-seeking from high cost settings e.g. general medical practices, emergency departments.  70 
The consequences of inappropriate NPM use are often explored using indirect measures 71 
because traditional methods of pharmacovigilance are less applicable due to the lack of 72 
documentation in patients’ medical records.  Previous research demonstrated that 6.5% of all 73 
emergency hospital admissions were due to adverse drug reactions (ADRs) and that the 74 
majority of these were associated with non-steroidal anti-inflammatory (NSAIDs), aspirin in 75 
particular [1].  Most NSAIDs (e.g. ibuprofen) implicated in these admissions are available as 76 
NPMs in the UK; low dose aspirin (75mg) is widely available internationally and contributed 77 
to the majority of NSAID-related harms primarily gastro-intestinal haemorrhage.  A recent 78 
Dutch study confirmed the use of NSAIDs by “high risk” patients and reiterated the need for 79 
patients to be warned about the risks of these medicines [2].  80 
 81 
Evidence suggests the sale/supply of NPMs from community pharmacies is sub-optimal 82 
irrespective of country, product or health condition [3, 4].  Managing NPM consultations is 83 
complex; pharmacists and their staff are often required to make recommendations based upon 84 
incomplete symptom information, other medical conditions, other medications being used, as 85 
well as the health status of clients.  The way in which clients “present” during consultations 86 
varies with some requesting a specific product (hereafter referred to as ‘direct product 87 
request’), while others seek advice to address symptoms or clinical condition.  Direct product 88 
requests, which account for the majority of NPM consultations, are less likely to result in an 89 
appropriate outcome i.e. supply of medicines consistent with best evidence, compared with 90 
advice-seeking requests [5].  This variation has been attributed to low rates of information 91 
disclosure during product requests [6].   92 
6 
 
 93 
Individual’s perceptions of the benefits and risks of medicines are likely to influence their 94 
treatment decisions.  For prescribed medicines, there is ample evidence that patients are less 95 
likely to engage appropriately if they believe there are risks; a recent meta-analysis found that 96 
patients with more concerns were less likely to adhere to the medicines regimen [7]. For NPMs, 97 
one study reported that 40% of Americans believed that NPMs were too weak to cause any real 98 
harm, and one-third took more than the recommended dose, believing it would increase 99 
effectiveness [8]. Whilst there has been some exploration of public perception of risk of NPMs 100 
[9-11], only one study to date has adopted a theoretical approach to exploring these beliefs 101 
[12], which applied the Theory of Planned Behaviour to exploring low-to-middle income 102 
women in Mexico’s risk perception of cold and flu remedies.  Whilst the majority of these 103 
studies have sought to explore sources of information used by the public to increase their 104 
knowledge of these medicines as a means of mitigating risk, none has explored the effect of 105 
risk perception on information disclosure during consultations. 106 
 107 
It is therefore important to understand individual and public risk perceptions of medicines so 108 
that interventions can be targeted to promote safe and effective use. The psychometric 109 
paradigm [13], proposes that the explanatory power of risk perception is clearer when scores 110 
are disaggregated to show differences between people separately from differences between 111 
hazards.  The psychological paradigm of risk [13] involves asking individuals to assess the 112 
relative risk associated with specific items, hazards or behaviours.  Within this paradigm, 113 
individuals make quantitative judgements of the risk associated with different hazards and their 114 
desired level of regulation for each of these hazards. 115 
 116 
The purpose of the present study was to: 117 
 Describe public risk perceptions of NPMs  118 
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 Explore the association between general risk perception, specific components ofrisk 119 
perception and information disclosure behaviour during consultations for NPMs 120 
Our hypothesis was that a lower risk perception of NPMs would be associated with reduced 121 
information disclosure information during consultations for NPMs.  122 
 123 
METHODS 124 
Design and Participants 125 
A cross-sectional population survey was conducted in 2008 to determine factors associated 126 
with buying NPMs and giving information to pharmacy staff when buying “pharmacy 127 
medicines”.  The questionnaire was informed by the Theory of Planned Behaviour (TPB) [14]. 128 
This theory identifies important determinants of voluntary behaviours such as information 129 
giving. The term “Pharmacy medicines” was used for NPMs and was defined as “medicines 130 
that can be bought from pharmacies (chemists) without a prescription”.  The TPB proposes that 131 
behaviour is predicted by behavioural intention which in turn is influenced by Perceived 132 
Behaviour Control (PBC) (i.e. whether the behaviour is difficult or easy to perform), subjective 133 
norm (SN) (i.e. whether important others consider the behaviour to be important) and attitude 134 
(ATT) towards the behaviour (i.e. whether engagement with the behaviour will achieve valued 135 
outcomes) (Figure 1).  136 
 137 
Using the Scottish Electoral register, a random sample was taken, stratified by sex. Adults aged 138 
≥18 years (one per household) and those not registered with the Mail Preference Service were 139 
approached. Postal questionnaires were mailed to 3000 participants with a 2:1 female to male 140 
ratio to reflect the population of people purchasing NPMs from community pharmacies [15, 141 
16].  The results presented here relate to respondents’ risk perceptions regarding NPMs. 142 
 143 
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Questionnaire Content and Administration 144 
The questionnaire collected the following information: 145 
 Risk perceptions of NPMs.  Risk was defined as “a situation that could expose you 146 
to harm or have an unpleasant outcome”.  147 
 Predictors  (based on the Theory of Planned Behaviour, [14, 17] of buying products 148 
and giving information using measures of attitudes and perceived behavioural control  149 
reported elsewhere [6]. 150 
 Demographic characteristics. 151 
 152 
A reminder letter was sent after two weeks and included a reply paid envelope. A second 153 
reminder letter, non-reply form and reply paid envelope were sent to non-responders after a 154 
further two weeks.  155 
 156 
Pharmacy medicines and risk 157 
 158 
Respondents were asked “in general how much risk do you think there is when using a 159 
pharmacy medicine” and was measured on a scale from one to seven, anchored by descriptive 160 
terms at extreme values only (1=low risk, 7=high risk).  They were also asked to state their 161 
agreement about the risk of 23 additional items related to NPMs, derived from the psychometric 162 
paradigm attributes [13].  Agreement was measured on a 7-point scale (1=strongly agree; 163 
7=strongly disagree) where agreement equates to low risk perception. Information disclosure 164 
(‘giving information’) was explored using constructs from the TPB [6]. Respondents were also 165 
asked an open question to name the NPMs which they considered to be associated with least 166 
and most risk. 167 
 168 
Data Management and Analysis 169 
 170 
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Data were entered and analysed in SPSS version 20 (IBM Corp. Released 2011. IBM SPSS 171 
Statistics for Windows, Version 20.0. Armonk, NY).  Demographics summarised using 172 
frequency and percentage for categorical variables, mean and standard deviation for age.  Risk 173 
questions were summarised using number and percentage responding in each category of the 174 
1-7 scale and mean agreement was calculated [18]. Two questions were reverse coded to align 175 
the interpretation (It is not possible to overdose with pharmacy medicines; There are no risks 176 
associated with using pharmacy medicines).  Two categories of risk perception were derived: 177 
low (1-3), high (4-7). The neutral category (4) was included within high risk, so that any 178 
observed effect would be a conservative estimate of association. 179 
 180 
Exploratory factor analysis was undertaken to determine whether responses could be grouped 181 
by constructs of risk.  A correlation matrix of responses to the 23 specific risk questions was 182 
obtained. An a priori decision was made to exclude a question from the factor analysis if its 183 
correlation coefficients with all other questions was <0.2 [20]. The Kaiser-Meyer-Olkin 184 
(KMO) test [19] and Bartlett’s test of sphericity [20] were conducted to test whether there was 185 
sufficient common variance and correlation to carry out the factor analysis. According to 186 
convention [21], a minimum level of 0.5 was used for the KMO test to indicate sufficient 187 
common variance. Cattell’s scree plot [21] and Kaiser’s eigenvalue [19] criterion were used to 188 
determine the number of factors to extract.  Factors were extracted using principal components 189 
analysis rotated with varimax rotation [22]. Items contained within factors were limited to those 190 
with a factor loading of >0.4 [20].  To generate a factor score the average of the identified 191 
statements within that factor was calculated for each respondent. For example, for a factor 192 
containing 4 items (a1, a2, a3, a4) the score was given by the following equation: score = (a1 + 193 
a2 + a3 + a4) / 4. Higher scores indicate higher perception of risk.  Univariate tests (Mann 194 
Whitney or Spearman’s rank correlation) were performed to determine the relationship 195 
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between factor scores and respondent demographics on information disclosure.  Multiple linear 196 
regression using forward selection (entry p<0.05) identified which demographics were 197 
predictive of factor scores.     198 
 199 
Sample size 200 
The factor analysis conducted for this study was based upon 21 questions resulting in six 201 
factors.  The recommended minimum sample size for conducting factor analysis using these 202 
parameters is 900 [23]. 203 
 204 
Ethical approval 205 
Ethical approval for this study was not required because the survey was conducted with 206 
publicly available data. 207 
 208 
RESULTS 209 
RESPONDENT CHARACTERISTICS 210 
The demographic characteristics of the 927 respondents are shown in Table 1. Respondents 211 
were aged between 19 and 96 years (mean 52.3, SD 16.1), three quarters of whom were female, 212 
almost all of whom were of white ethnic origin.  The majority (69%) were married/ living with 213 
partner with 48% having no formal qualification or only school-level education.  Just over half 214 
reported their health to be very good or excellent.  Nearly half (49%) had used a pharmacy in 215 
the previous 14 days and 43% had bought a NPM in the previous month. 216 
 217 
 218 
Public Perceptions of Risk of NPMs 219 
In response to the general risk question, over half the respondents indicated there was low risk 220 
to using NPMs (57.0%), with 23.9% remaining neutral and 19.0% indicating high risk 221 
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response.  The majority (19/23) of statements had a mean score <4 on the 7 point scale 222 
indicating general agreement with these statements i.e. low risk perception of OTC medicines.  223 
The four statements with which respondents tended to disagree were: “the risks associated with 224 
using pharmacy medicines are likely to be fatal”, “there is more risk involved with using 225 
pharmacy medicines than there was 10 years ago”, “people who use pharmacy medicines 226 
know precisely what risks are associated with them” and “the risks associated with using 227 
pharmacy medicines affect me personally”.  There was strong agreement (>70%) with 11 228 
statements and strong disagreement (>70%) with two statements (Table 2).  Figure 2 shows the 229 
mean agreement for the general risk statement followed by each statement (ordered from most 230 
agreement at the bottom to least agreement at the top). 231 
 232 
Identifying risk components: Factor analysis 233 
Two statements, “Pharmacy medicines can be addictive” and “Pharmacy medicines that used 234 
to be available on prescription have greater risk than medicines that have been available with 235 
our prescription for many years” showed correlation < 0.2 with other items were and were 236 
excluded from the factor analysis. The factor analysis of the remaining 21 statements produced 237 
a KMO measure of sampling adequacy of 0.781 which is considered good and Bartlett test of 238 
sphericity was p<0.001, indicating factor analysis was appropriate. The eigenvalue >1 rule and 239 
the scree plot indicated that six factors should be extracted totalling 58.2% of the variance using 240 
a varimax rotation.  241 
 242 
Table 2 shows the six identified factors and their loadings, with loadings <0.4 suppressed for 243 
clarity. The first factor (Personal Acceptance) contributed 16.5% of the variance and consisted 244 
of items around acceptance, benefit and comfort with Pharmacy medicines. The second factor 245 
(General risk perception) consisted of statements relating to a general view of risk and 246 
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contributed an additional 15.9% of the variance. The third factor (Populations and behavioural 247 
risk factors) contributed 8.3% of the variance and contained statements relating to risk in 248 
specific populations such as children and pregnant women.  The fourth factor (Adherence) (i.e. 249 
adherence to giving information) was mainly related to using information to manage risk and 250 
contributed 6.7% of the variance. The fifth factor (Denial of risk) contributed to 6.0% of 251 
variance and the sixth factor (Individual- and population-risk) contributed the final 4.9% of the 252 
total variance.   253 
 254 
 255 
Do individual characteristics predict risk perception? 256 
Univariate analyses of the relationship between demographic variables and factor scores was 257 
undertaken. No significant gender difference (p>0.05) was found. Older respondents were 258 
significantly more likely to agree (equating to lower risk perception) with the statements 259 
associated with three factors: General risk (p=0.004), Population and behaviour risk factors 260 
(p<0.001), Adherence (p=0.033). Respondents with post-school education showed 261 
significantly higher risk perception for Adherence (p=0.001) compared with those with no 262 
formal or only school level education, but had lower scores (lower risk perception) for General 263 
Risk Perception (p=0.02) and Individual- and population-risk (p=0.03). Those married/living 264 
with partner showed significantly lower scores for Personal Acceptance (p=0.016).   265 
 266 
For health status, respondents reporting good/very good/excellent status compared with 267 
fair/poor were significantly more likely to agree (lower risk perception) with the statements 268 
associated with the factors: Personal Acceptance (p=0.02) and Populations and Behaviour Risk 269 
Factors (p=0.002), and to disagree (higher risk perception) with statements associated with 270 
Denial (p=0.033).   271 
13 
 
 272 
Six multiple linear regression was used to investigate the combined effects of these 273 
demographic variables in predicting each of the six factor scores (Table 3).  Age was an 274 
important predictor for General Risk Perception, Populations and Behaviour Risk Factors, 275 
Denial and Individual- and Population-risk with older age indicating greater agreement/ lower 276 
risk perception (as indicated by the negative coefficients).  Gender was only important for 277 
Adherence, with females indicating more agreement i.e. higher risk perception.  Education was 278 
important for General Risk Perception and Individual- and Population-risk with greater 279 
education levels associated with greater agreement/higher risk perception. Health status was 280 
significant for Personal Acceptance and Denial with those in good/very good/excellent health 281 
indicating more agreement.  In each case, the R-square was low (<5%) but the ANOVA p-282 
value was significant indicating that the demographics explained a low, but statistically 283 
significant, percentage of variability in the factor scores.   284 
 285 
Does risk perception predict behaviour (information giving)? 286 
Respondents with overall low risk perception were significantly more likely to have disclosed 287 
information during their last pharmacy consultation than those with higher risk perception: 288 
41.2% versus 33% (p=0.032).  No statistically significant differences in factor scores occurred 289 
between respondents who disclosed and those that did not.  290 
 291 
Does risk perception predict behavioural determinants (TPB variables)? 292 
Respondents who perceived NPMs to be associated with low risk had significantly higher 293 
attitude (p=0.003) and perceived behavioural control scores (p=0.01) regarding giving 294 
information to medicine counter assistants (MCAs). This means that respondents who were 295 
categorised as “low risk” believed that giving information would achieve better outcomes. 296 
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There was some indication that respondents’ with low risk perception had higher intention to 297 
disclose information than those who perceived NPMs to be of high risk (p=0.05).   298 
 299 
DISCUSSION  300 
Main results 301 
This is the first theoretically-underpinned study to explore public risk perception of NPMs and 302 
information disclosure.  The results showed that, in general, NPMs were perceived to be 303 
associated with low risk and that low risk perception was associated with higher tendency to 304 
disclose information thus disproving our hypothesis.  In a study about patient information 305 
leaflets, people who were more worried about adverse effects were less likely to read the leaflet. 306 
This fits with the idea that high risk perception is linked to a lack of engagement with 307 
information, which reflects our finding that low risk perception was associated with higher 308 
tendency to disclose information [24]. Another study found low risk perception may be 309 
associated with higher tendency to disclose information due to variations in ‘regulatory’ focus, 310 
i.e. the extent to which individuals seek to promote positive or prevent negative comments. In 311 
promotion focus, they are more prepared to take risks and to engage in promotion activities 312 
such as giving information [25]. 313 
  314 
Limitations/strengths 315 
These data were collected in 2008 and have undergone substantial analysis and iterations. 316 
Whilst a survey of general risk perception of NPMs in the UK was conducted in 2013 [26], 317 
there are no published studies of in-depth risk perception as reported in the current study.  As 318 
such we believe the results are important and provide a unique contribution to existing 319 
knowledge. Furthermore,in the intervening period, no major changes have occurred with NPMs 320 
in Scotland/UK in general, although tighter restrictions have been introduced for some 321 
medicines associated with misuse e.g. pseudoephedrine (https://www.gov.uk/drug-safety-322 
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update/pseudoephedrine-and-ephedrine-update-on-managing-risk-of-misuse), the age limit 323 
was raised limit for cough remedies for children (https://www.gov.uk/drug-safety-update/over-324 
the-counter-cough-and-cold-medicines-for-children) and diclofenac was reclassified to 325 
Prescription Only Medicine status because of new evidence regarding cardiovascular toxicity 326 
(https://www.gov.uk/government/news/diclofenac-tablets-now-only-available-as-a-327 
prescription-medicine).   328 
 329 
This current study was conducted in Scotland and few respondents were from ethnic minorities 330 
thus the effect of ethnicity could not be explored, but has been shown previously to influence 331 
risk perception of prescription medicines [18].  A 2:1 female: male sampling strategy was used 332 
(to reflect the higher rates of pharmacy and medicine use by females) and generated more 333 
female than male respondents. Furthermore, respondents were more likely to be older and to 334 
be married or living with someone.  These characteristics mean that these results might not be 335 
generalisable to individuals from ethnic minorities, people who are living alone, or younger 336 
individuals.  Bias may have been introduced into the sample through the use of the electoral 337 
register, however, it was the most inclusive method available for this survey.  The study had 338 
sufficient power (based upon the derived sample size of 927) to conduct the factor analysis 339 
which generated six factors and explained 58% of the variation. 340 
 341 
Comparison with literature 342 
A much higher proportion of respondents (71.4%) in our study agreed that there was “no risk 343 
with pharmacy medicines” compared with an earlier survey which showed that only 47.4% of 344 
respondents agreed/strongly agreed that “non-prescription medicines are totally safe to use” 345 
[27]. Our results suggest that individual respondents’ perceive themselves to be at less risk 346 
from NPMs compared with the wider population. This finding is congruent with an earlier 347 
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study suggesting that consumers were critical of the public’s ability to self-medicate safely and 348 
appropriately using NPMs [28]. All NPMs were treated as one group in this current study.  349 
Slovic et al [18] included four medicines available in non-prescription form and explored 350 
differences in risk perceptions between them.  Other studies have compared risk perception of 351 
NPMs versus prescription only medicines but have demonstrated conflicting results, with some 352 
showing public perception of risk to be greater with POMs compared with NPMs [11], whilst 353 
others report the converse [12].  An earlier study of individuals who used a NPM for the relief 354 
of hay-fever (terfenadine) which was subsequently reclassified back to prescription medicine 355 
status because of adverse effects, expressed concern about the previously unknown risks with 356 
the use of the drug [28].  Their risk perceptions of NPMs also changed as a result of the 357 
reclassification of this medicine.   358 
 359 
Implications for policy, practice and research 360 
These results highlight a need to increase public awareness regarding the use of NPMs as well 361 
as the importance of sharing information during NPM consultations.  Pharmacy personnel need 362 
to actively seek relevant information from consumers to inform their decisions regarding the 363 
appropriate treatment and research is ongoing to explore strategies which influence both 364 
service provider and user behaviour during these consultations.      365 
 366 
CONCLUSION 367 
There is general low public risk perception of NPMs.  Interventions that target risk perception 368 
are unlikely to enhance the safe and effective supply of these medicines because they will not 369 
enhance information disclosure during consultations.  Alternative strategies are needed to 370 
enhance the public’s health literacy regarding these medicines and the importance of 371 
information disclosure to maximise their safe and effective use. 372 
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Table 1: Respondent demographics n (%) 435 
 436 
  N = 927 
Gender (n = 895) 
Male 241 (27) 
Female 654 (73) 
  
Marital status (n = 894) 
Single 134 (15) 
Married/living with partner 612 (69) 
Divorced/separated 67 (8) 
Widowed 81 (9) 
  
Highest educational qualification (n = 914) 
No formal education 162 (18) 
School level 274 (30) 
post School (non-university) 102 (11) 
University degree 229 (25) 
Other 134 (15) 
  
Ethnic group (n = 914) 
White 903 (99) 
Other 11 (1) 
  
Health status (n = 913) 
Excellent 107 (12) 
Very good 357 (39) 
Good 300 (33) 
fair/poor 149 (16) 
  
Age (years) (n = 892) 
Mean (SD) 53.2 (16.1) 
 437 
 438 
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Table 2: Pharmacy Medicines, mean agreement of risk perception and factor loadings  
 
   Factor Loadings using Varimax Rotation 
   1 2 3 4 5 6 
Question Total N 
Mean 
Agreement** 
Personal 
Acceptance 
Medicines
’ Risk 
Population and 
behaviour risk 
factors Adherence Denial 
Individual- and 
population-risk 
In general how much risk do you think 
there is when using pharmacy medicines 829 3.23       
         
The risks associated with using pharmacy 
medicines are acceptable to me 828 2.83 0.848      
I can deal with the risks of using 
pharmacy medicines 833 2.87 0.822      
I feel comfortable with the level of risk 
associated with using pharmacy 
medicines 835 2.60 0.812      
Using pharmacy medicines is beneficial 
to me 841 2.49 0.622      
It is up to me whether I put myself at 
risk due to using pharmacy medicines 834 2.72 0.425 0.435     
People who use pharmacy medicines 
know precisely what risks are associated 
with them 834 4.27 0.423    0.532  
There is more risk involved in using 
pharmacy medicine than there was 10 
years ago 829 4.59  0.665     
Using pharmacy medicines could harm 
people 827 3.66  0.653     
The risks associated with using pharmacy 
medicines may not be understood until 
much later 835 3.36  0.633     
The risks associated with using 
pharmacy medicines are likely to be 
fatal 831 5.12  0.594     
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Everyone who uses a pharmacy medicine 
could be at risk from these medicines 831 3.60  0.407    0.598 
Children are at greater risk than adults 
when using pharmacy medicines 836 2.92   0.853    
Pregnant women are at greater risk 
when using pharmacy medicines 834 2.62   0.838    
Using a pharmacy medicine and 
driving can be risky 868 2.59   0.565    
Drinking alcohol whilst using 
pharmacy medicines can be risky 845 1.90   0.550 0.457   
When using pharmacy medicines, I 
always use the recommended dose 842 1.56    0.757   
Pharmacy medicines are less risky if 
you follow the instructions when using 
them 838 1.68    0.629   
If I do not follow the instructions when 
using pharmacy medicines I will be 
putting myself at risk of harm 843 1.95    0.624   
It is not possible to overdose with 
pharmacy medicines* 836 1.77     0.763  
There are no risks associated with 
using pharmacy medicines* 826 2.64     0.692  
The risks associated with using pharmacy 
medicines affect me personally 817 4.14      0.875 
Pharmacy medicines can be addictive 832 3.00 Not included in factor analysis  
Pharmacy medicines that used to be 
available on prescription have greater 
risk than medicines that have been 
available without a prescription for many 
years 855 3.76 Not included in factor analysis 
 *Reverse coded to enable comparable interpretation   
** Agreement: Strongly agree (1) to Strongly Disagree (7) 
 Bold indicates statements with > 70% agreement/disagreement
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Table 3: Regression coefficients (SE) for models examining the predictive ability of demographic factors on each factor score 
 
  
Factor 1 
Personal 
Acceptance 
Factor 2 
General 
Risk 
Perception 
Factor 3 
Population 
and 
Behaviour 
Risk 
Factors 
 
Factor 4 
Adherence 
Factor 5 
Denial 
Factor 6 
Individual 
and 
Population 
Risk 
N 802 805 826 830 814 812 
R-square 0.007 0.022 0.03 0.012 0.008 0.013 
ANOVA F  
p-value 
5.53 
 0.019 
9.10 
<0.001 
25.7 
<0.001 4.96 0.007 6.93 0.009 5.21 0.006 
Constant 
3.19  
(0.10) 
4.41 
(0.14) 
3.21 
(0.15) 
2.27 
(0.16) 
3.09 
(0.08) 
4.46 
(0.21) 
 
 
Gender       
Female       
-0.155 
(0.07)     
Age       
per year   
-0.008 
(0.08) 
-0.014 
(0.003) 
-0.004 
(0.002)   
-0.008 
(0.11) 
Health       
Good/very 
good/excellent 
-0.249 
(0.11)       
-0.235 
(0.09)   
Education       
Post school   
-0.238 
(0.002)       
-0.29 
(0.004) 
NB: Marital status was not selected by any model so is not included in this table 
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FIGURES 
 
Figure 1: Theory of Planned Behaviour  
 
 
 
24 
 
 
Figure 2 Respondents’ mean agreement with risk perception statements (1 = strongly agree to 7 strongly disagree) 
*Reverse coded to enable comparable interpretation 
 
*Reverse coded to enable comparable interpretation 
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When using pharmacy medicines, I always use the recommended dose
Pharmacy medicines are less risky if you follow the instructions when using them
It is not possible to overdose with pharmacy medicines*
Drinking alcohol whilst using pharmacy medicines can be risky
If I do not follow the instructions when using pharmacy medicines I will be…
Using pharmacy medicines is beneficial to me
Using a pharmacy medicine and driving can be risky
I feel comfortable with the level of risk associated with using pharmacy medicines
Pregnant women are at greater risk when using pharmacy medicines
There are no risks associated with using pharmacy medicines*
It is up to me whether I put myself at risk due to using pharmacy medicines
The risks associated with using pharmacy medicines are acceptable to me
I can deal with the risks of using pharmacy medicines
Children are at greater risk than adults when using pharmacy medicines
Pharmacy medicines can be addictive
The risks associated with using pharmacy medicines may not be understood…
Everyone who uses a pharmacy medicine could be at risk from these medicines
Using pharmacy medicines could harm people
Pharmacy medicines that used to be available on prescription have greater risk…
The risks associated with using pharmacy medicines affect me personally
People who use pharmacy medicines know precisely what risks are associated…
There is more risk involved in using pharmacy medicine than there was 10 years…
The risks associated with using pharmacy medicines are likely to be fatal
In general how much risk do you think there is when using pharmacy medicines
Mean Agreement 
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